## Howard C Herrmann, Fscai

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8771347/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Transcatheter Aortic-Valve Implantation for Aortic Stenosis in Patients Who Cannot Undergo Surgery. New England Journal of Medicine, 2010, 363, 1597-1607.	13.9	6,189
2	Transcatheter versus Surgical Aortic-Valve Replacement in High-Risk Patients. New England Journal of Medicine, 2011, 364, 2187-2198.	13.9	5,447
3	Transcatheter or Surgical Aortic-Valve Replacement in Intermediate-Risk Patients. New England Journal of Medicine, 2016, 374, 1609-1620.	13.9	3,992
4	Rapid Measurement of B-Type Natriuretic Peptide in the Emergency Diagnosis of Heart Failure. New England Journal of Medicine, 2002, 347, 161-167.	13.9	3,057
5	5-year outcomes of transcatheter aortic valve replacement or surgical aortic valve replacement for high surgical risk patients with aortic stenosis (PARTNER 1): a randomised controlled trial. Lancet, The, 2015, 385, 2477-2484.	6.3	1,388
6	Transcatheter Aortic-Valve Replacement for Inoperable Severe Aortic Stenosis. New England Journal of Medicine, 2012, 366, 1696-1704.	13.9	1,179
7	Closure or Medical Therapy for Cryptogenic Stroke with Patent Foramen Ovale. New England Journal of Medicine, 2012, 366, 991-999.	13.9	916
8	Transcatheter aortic valve replacement versus surgical valve replacement in intermediate-risk patients: a propensity score analysis. Lancet, The, 2016, 387, 2218-2225.	6.3	899
9	Percutaneous Mitral Repair With the MitraClip System. Journal of the American College of Cardiology, 2009, 54, 686-694.	1.2	852
10	B-Type Natriuretic Peptide and Clinical Judgment in Emergency Diagnosis of Heart Failure. Circulation, 2002, 106, 416-422.	1.6	811
11	ACC/AHA guidelines for coronary artery bypass graft surgery. Journal of the American College of Cardiology, 1999, 34, 1262-1347.	1.2	775
12	5-year outcomes of transcatheter aortic valve replacement compared with standard treatment for patients with inoperable aortic stenosis (PARTNER 1): a randomised controlled trial. Lancet, The, 2015, 385, 2485-2491.	6.3	724
13	ACC/AHA 2004 Guideline Update for Coronary Artery Bypass Graft Surgery: Summary Article. Circulation, 2004, 110, 1168-1176.	1.6	699
14	Percutaneous Mitral Valve Repair Using the Edge-to-Edge Technique. Journal of the American College of Cardiology, 2005, 46, 2134-2140.	1.2	693
15	Comparison of Two Platelet Glycoprotein IIb/IIIa Inhibitors, Tirofiban and Abciximab, for the Prevention of Ischemic Events with Percutaneous Coronary Revascularization. New England Journal of Medicine, 2001, 344, 1888-1894.	13.9	675
16	Randomized Comparison of Percutaneous Repair and Surgery for Mitral Regurgitation. Journal of the American College of Cardiology, 2015, 66, 2844-2854.	1.2	658
17	Preload dependence of doppler-derived indexes of left ventricular diastolic function in humans. Journal of the American College of Cardiology, 1987, 10, 800-808.	1.2	652
18	Facilitated PCI in Patients with ST-Elevation Myocardial Infarction. New England Journal of Medicine, 2008, 358, 2205-2217.	13.9	596

#	Article	IF	CITATIONS
19	Five-Year Outcomes of Transcatheter or Surgical Aortic-Valve Replacement. New England Journal of Medicine, 2020, 382, 799-809.	13.9	520
20	Acute and 12-Month Results With Catheter-Based Mitral Valve Leaflet Repair. Journal of the American College of Cardiology, 2012, 59, 130-139.	1.2	518
21	STS-ACC TVT Registry of Transcatheter Aortic Valve Replacement. Journal of the American College of Cardiology, 2020, 76, 2492-2516.	1.2	511
22	B-type natriuretic peptide and renal function in the diagnosis of heart failure: An analysis from the breathing not properly multinational study. American Journal of Kidney Diseases, 2003, 41, 571-579.	2.1	464
23	Predictors and Clinical Outcomes of Permanent Pacemaker Implantation After Transcatheter Aortic Valve Replacement. JACC: Cardiovascular Interventions, 2015, 8, 60-69.	1.1	441
24	Bedside B-Type natriuretic peptide in the emergency diagnosis of heart failure with reduced or preserved ejection fraction. Journal of the American College of Cardiology, 2003, 41, 2010-2017.	1.2	429
25	4-Year Results of a Randomized Controlled Trial of Percutaneous Repair Versus Surgery for Mitral Regurgitation. Journal of the American College of Cardiology, 2013, 62, 317-328.	1.2	411
26	Protection Against Cerebral Embolism During Transcatheter Aortic Valve Replacement. Journal of the American College of Cardiology, 2017, 69, 367-377.	1.2	405
27	ACC/AHA Guidelines for Coronary Artery Bypass Graft Surgery: Executive Summary and Recommendations. Circulation, 1999, 100, 1464-1480.	1.6	376
28	Predictors of Mortality and Outcomes of Therapy in Low-Flow Severe Aortic Stenosis. Circulation, 2013, 127, 2316-2326.	1.6	373
29	Staging classification of aortic stenosis based on the extent of cardiac damage. European Heart Journal, 2017, 38, 3351-3358.	1.0	364
30	A Controlled Trial of Rivaroxaban after Transcatheter Aortic-Valve Replacement. New England Journal of Medicine, 2020, 382, 120-129.	13.9	362
31	Randomized Comparison of Distal Protection With a Filter-Based Catheter and a Balloon Occlusion and Aspiration System During Percutaneous Intervention of Diseased Saphenous Vein Aorto-Coronary Bypass Grafts. Circulation, 2003, 108, 548-553.	1.6	361
32	Incidence and Sequelae of Prosthesis-Patient Mismatch in Transcatheter Versus Surgical Valve Replacement in High-Risk Patients With Severe Aortic Stenosis. Journal of the American College of Cardiology, 2014, 64, 1323-1334.	1.2	317
33	Hemodynamic Effects of Sildenafil in Men with Severe Coronary Artery Disease. New England Journal of Medicine, 2000, 342, 1622-1626.	13.9	313
34	Early clinical and echocardiographic outcomes after SAPIEN 3 transcatheter aortic valve replacement in inoperable, high-risk and intermediate-risk patients with aortic stenosis. European Heart Journal, 2016, 37, 2252-2262.	1.0	305
35	Health-Related Quality of Life After Transcatheter Aortic Valve Replacement in Inoperable Patients With Severe Aortic Stenosis. Circulation, 2011, 124, 1964-1972.	1.6	278
36	Improved Functional Status and Quality of Life in Prohibitive Surgical Risk Patients With Degenerative Mitral Regurgitation After Transcatheter Mitral Valve Repair. Journal of the American College of Cardiology, 2014, 64, 182-192.	1.2	274

#	Article	IF	CITATIONS
37	Transcatheter Aortic Valve Implantation Within Degenerated Aortic Surgical Bioprostheses. Journal of the American College of Cardiology, 2017, 69, 2253-2262.	1.2	271
38	Procedural Volume and Outcomes for Transcatheter Aortic-Valve Replacement. New England Journal of Medicine, 2019, 380, 2541-2550.	13.9	263
39	ACC/AHA 2004 guideline update for coronary artery bypass graft surgery: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to) Tj ETQq1 1 (	0.71 <b>86</b> 4314 (	rg₿₮dOverloo
40	Benefit of an Early Invasive Management Strategy in Women With Acute Coronary Syndromes. JAMA - Journal of the American Medical Association, 2002, 288, 3124.	3.8	248
41	Association Between Transcatheter Aortic Valve Replacement and Subsequent Infective Endocarditis and In-Hospital Death. JAMA - Journal of the American Medical Association, 2016, 316, 1083.	3.8	241
42	How obesity affects the cut-points for B-type natriuretic peptide in the diagnosis of acute heart failure. American Heart Journal, 2006, 151, 999-1005.	1.2	238
43	Infective Endocarditis After Transcatheter Aortic Valve Implantation. Circulation, 2015, 131, 1566-1574.	1.6	227
44	Randomized, double-blind, placebo-controlled dose-ranging study of tirofiban (MK-383) platelet IIb/IIIa blockade in high risk patients undergoing coronary angioplasty. Journal of the American College of Cardiology, 1996, 27, 536-542.	1.2	222
45	Impact of age, race, and sex on the ability of B-type natriuretic peptide to aid in the emergency diagnosis of heart failure: results from the Breathing Not Properly (BNP) multinational study. American Heart Journal, 2004, 147, 1078-1084.	1.2	221
46	Comparison of Transcatheter and SurgicalÂAortic Valve Replacement in SevereÂAorticÂStenosis. Journal of the American College of Cardiology, 2013, 61, 2514-2521.	1.2	218
47	Prosthesis–Patient Mismatch inÂPatientsÂUndergoing TranscatheterÂAorticÂValve Replacement. Journal of the American College of Cardiology, 2018, 72, 2701-2711.	1.2	216
48	Intravascular Lithotripsy for Treatment of Severely Calcified CoronaryÂArtery Disease. Journal of the American College of Cardiology, 2020, 76, 2635-2646.	1.2	209
49	Outcomes 2 Years After Transcatheter Aortic Valve Replacement in Patients at Low Surgical Risk. Journal of the American College of Cardiology, 2021, 77, 1149-1161.	1.2	204
50	Echocardiographic Guidance and Assessment of Percutaneous Repair for Mitral Regurgitation With the Evalve MitraClip: Lessons Learned From EVEREST I. Journal of the American Society of Echocardiography, 2007, 20, 1131-1140.	1.2	200
51	Quantitative Assessment of Severity of Mitral Regurgitation by Serial Echocardiography in a Multicenter Clinical Trial of Percutaneous Mitral Valve Repair. American Journal of Cardiology, 2007, 100, 1577-1583.	0.7	198
52	Echocardiography-Guided Interventions. Journal of the American Society of Echocardiography, 2009, 22, 213-231.	1.2	195
53	Conscious Sedation Versus General Anesthesia for Transcatheter Aortic Valve Replacement. Circulation, 2017, 136, 2132-2140.	1.6	184
54	Facilitation of early percutaneous coronary intervention after reteplase with or without abciximab in acute myocardial infarction. Journal of the American College of Cardiology, 2000, 36, 1489-1496.	1.2	178

#	Article	IF	CITATIONS
55	The Acute Hemodynamic Effects of MitraClip Therapy. Journal of the American College of Cardiology, 2011, 57, 1658-1665.	1.2	176
56	One-Year Clinical Outcomes With SAPIEN 3 Transcatheter Aortic Valve Replacement in High-Risk and Inoperable Patients With Severe Aortic Stenosis. Circulation, 2016, 134, 130-140.	1.6	172
57	The future of transcatheter mitral valve interventions: competitive or complementary role of repair vs. replacement?. European Heart Journal, 2015, 36, 1651-1659.	1.0	168
58	Percutaneous balloon pericardiotomy for the treatment of cardiac tamponade and large pericardial effusions: Description of technique and report of the first 50 cases. Journal of the American College of Cardiology, 1993, 21, 1-5.	1.2	165
59	Subclinical Leaflet Thrombosis in Transcatheter and Surgical BioprostheticÂValves. Journal of the American College of Cardiology, 2020, 75, 3003-3015.	1.2	165
60	Long-Term Outcomes of Inoperable Patients With Aortic Stenosis Randomly Assigned to Transcatheter Aortic Valve Replacement or Standard Therapy. Circulation, 2014, 130, 1483-1492.	1.6	158
61	Association of Paravalvular Regurgitation With 1-Year Outcomes After Transcatheter Aortic Valve Replacement With the SAPIEN 3 Valve. JAMA Cardiology, 2017, 2, 1208.	3.0	155
62	Transcatheter Aortic Valve Replacement in Patients With Low-Flow, Low-Gradient AorticÂStenosis. Journal of the American College of Cardiology, 2018, 71, 1297-1308.	1.2	152
63	Insights Into Timing, Risk Factors, and Outcomes of Stroke and Transient Ischemic Attack After Transcatheter Aortic Valve Replacement in the PARTNER Trial (Placement of Aortic Transcatheter) Tj ETQq1 1 0.74	84344 rgB	T 105 erlock
64	Percutaneous Transcatheter Mitral Valve Replacement. Circulation: Cardiovascular Interventions, 2014, 7, 400-409.	1.4	142
65	Uncovering Heart Failure in Patients with a History of Pulmonary Disease: Rationale for the Early Use of B-type Natriuretic Peptide in the Emergency Department. Academic Emergency Medicine, 2003, 10, 198-204.	0.8	142
66	Determinants and Outcomes of Acute Transcatheter Valve-in-Valve Therapy orÂEmbolization. Journal of the American College of Cardiology, 2013, 62, 418-430.	1.2	140
67	3-Year Outcomes After Valve-in-Valve Transcatheter Aortic Valve Replacement for Degenerated Bioprostheses. Journal of the American College of Cardiology, 2019, 73, 2647-2655.	1.2	123
68	One-Year Safety and Clinical Outcomes of a Transcatheter Interatrial Shunt Device for the Treatment of Heart Failure With Preserved Ejection Fraction in the Reduce Elevated Left Atrial Pressure in Patients With Heart Failure (REDUCE LAP-HF I) Trial. JAMA Cardiology, 2018, 3, 968.	3.0	121
69	Cost-Effectiveness of Transcatheter Versus Surgical Aortic Valve Replacement in Patients With Severe Aortic Stenosis at Intermediate Risk. Circulation, 2019, 139, 877-888.	1.6	120
70	Structural Deterioration of Transcatheter Versus Surgical Aortic Valve Bioprostheses in the PARTNER-2 Trial. Journal of the American College of Cardiology, 2020, 76, 1830-1843.	1.2	119
71	Effect of percutaneous mitral repair with the MitraClip® device on mitral valve area and gradient. EuroIntervention, 2009, 4, 437-442.	1.4	118
72	Chronic pacing and adverse outcomes after transcatheter aortic valve implantation. Heart, 2015, 101, 1665-1671.	1.2	117

5

#	Article	IF	CITATIONS
73	Transcatheter Versus Surgical Aortic-Valve Replacement in High-Risk Patients. Survey of Anesthesiology, 2012, 56, 4-5.	0.1	113
74	Correlates of Bleeding Events Among Moderate- to High-Risk Patients Undergoing Percutaneous Coronary Intervention and Treated With Eptifibatide. Journal of the American College of Cardiology, 2006, 47, 2374-2379.	1.2	110
75	Factors influencing immediate results, complications, and short-term follow-up status after inoue balloon mitral valvotomy: A North American multicenter study. American Heart Journal, 1992, 124, 160-166.	1.2	108
76	Effect of Thromboxane A <sub>2</sub> Blockade on Clinical Outcome and Restenosis After Successful Coronary Angioplasty. Circulation, 1995, 92, 3194-3200.	1.6	106
77	Health Status Benefits of Transcatheter vs Surgical Aortic Valve Replacement in Patients With Severe Aortic Stenosis at Intermediate Surgical Risk. JAMA Cardiology, 2017, 2, 837.	3.0	105
78	New-onset left bundle branch block after transcatheter aortic valve replacement is associated with adverse long-term clinical outcomes in intermediate-risk patients: an analysis from the PARTNER II trial. European Heart Journal, 2019, 40, 2218-2227.	1.0	103
79	Impact of Ejection Fraction and AorticÂValve Gradient on Outcomes of Transcatheter Aortic Valve Replacement. Journal of the American College of Cardiology, 2016, 67, 2349-2358.	1.2	97
80	How to Define a Poor Outcome After Transcatheter Aortic Valve Replacement. Circulation: Cardiovascular Quality and Outcomes, 2013, 6, 591-597.	0.9	96
81	Hormonal control of angiotensinogen production. Life Sciences, 1982, 30, 577-584.	2.0	92
82	Mechanisms and outcome of severe mitral regulation after inoue balloon valvuloplasty. Journal of the American College of Cardiology, 1993, 22, 783-789.	1.2	92
83	Heterogeneity of Treatment Effects in an Analysis of Pooled Individual Patient Data From Randomized Trials of Device Closure of Patent Foramen Ovale After Stroke. JAMA - Journal of the American Medical Association, 2021, 326, 2277.	3.8	92
84	STS-ACC TVT Registry of Transcatheter Aortic Valve Replacement. Annals of Thoracic Surgery, 2021, 111, 701-722.	0.7	91
85	A Randomized Evaluation of the SAPIEN XT Transcatheter Heart Valve System in Patients With Aortic Stenosis Who Are NotÂCandidates for Surgery. JACC: Cardiovascular Interventions, 2015, 8, 1797-1806.	1.1	90
86	Transcatheter Mitral Valve Therapy inÂtheÂUnited States. Journal of the American College of Cardiology, 2021, 78, 2326-2353.	1.2	90
87	Facilitated percutaneous coronary intervention versus primary percutaneous coronary intervention: design and rationale of the facilitated intervention with enhanced reperfusion speed to stop events (FINESSE) trial. American Heart Journal, 2004, 147, 684.	1.2	88
88	Impact of Different Platelet Glycoprotein IIb/IIIa Receptor Inhibitors Among Diabetic Patients Undergoing Percutaneous Coronary Intervention. Circulation, 2002, 105, 2730-2736.	1.6	87
89	Inoue balloon mitral valvotomy in patients with severe valvular and subvalvular deformity. Journal of the American College of Cardiology, 1995, 25, 1129-1136.	1.2	85
90	Mitral valve hemodynamic effects of percutaneous edge-to-edge repair with the MitraClipâ,,¢ device for mitral regurgitation. Catheterization and Cardiovascular Interventions, 2006, 68, 821-828.	0.7	83

#	Article	IF	CITATIONS
91	Outcomes With Post-Dilation Following Transcatheter Aortic Valve Replacement. JACC: Cardiovascular Interventions, 2014, 7, 781-789.	1.1	83
92	Clinical use of AcuNav diagnostic ultrasound catheter imaging during left heart radiofrequency ablation and transcatheter closure procedures. Journal of the American Society of Echocardiography, 2002, 15, 1301-1308.	1.2	81
93	Outcomes at 6 months for the direct comparison of tirofiban and abciximab during percutaneous coronary revascularisation with stent placement: the TARGET follow-up study. Lancet, The, 2002, 360, 355-360.	6.3	80
94	Comprehensive Analysis of Mortality Among Patients Undergoing TAVR. Journal of the American College of Cardiology, 2014, 64, 158-168.	1.2	80
95	Phase I Drug and Light Dose-Escalation Trial of Motexafin Lutetium and Far Red Light Activation (Phototherapy) in Subjects With Coronary Artery Disease Undergoing Percutaneous Coronary Intervention and Stent Deployment. Circulation, 2003, 108, 1310-1315.	1.6	77
96	ORIGINAL RESEARCH—ED PHARMACOTHERAPY: Can Atorvastatin Improve the Response to Sildenafil in Men with Erectile Dysfunction Not Initially Responsive to Sildenafil? Hypothesis and Pilot Trial Results. Journal of Sexual Medicine, 2006, 3, 303-308.	0.3	77
97	Benefit of Facilitated Percutaneous Coronary Intervention in High-Risk ST-Segment Elevation Myocardial Infarction Patients Presenting to Nonpercutaneous Coronary Intervention Hospitals. JACC: Cardiovascular Interventions, 2009, 2, 917-924.	1.1	76
98	Impact of Preoperative Chronic Kidney Disease in 2,531 High-Risk and Inoperable Patients Undergoing Transcatheter Aortic Valve Replacement in the PARTNER Trial. Annals of Thoracic Surgery, 2016, 102, 1172-1180.	0.7	75
99	Prosthetic Valve Endocarditis After TAVR and SAVR. Circulation, 2019, 140, 1984-1994.	1.6	75
100	Hemodynamic and renal effects of atrial natriuretic peptide in congestive heart failure. American Journal of Cardiology, 1990, 65, 211-216.	0.7	71
101	The M-heart percutaneous balloon mitral valvuloplasty registry: Initial results and early follow-up. Journal of the American College of Cardiology, 1990, 15, 1221-1226.	1.2	71
102	Increased concentrations of tirofiban in blood and their correlation with inhibition of platelet aggregation after greater bolus doses of tirofiban. American Journal of Cardiology, 2003, 91, 334-336.	0.7	71
103	Longitudinal Hemodynamics of Transcatheter and Surgical Aortic Valves in the PARTNER Trial. JAMA Cardiology, 2017, 2, 1197.	3.0	70
104	Q-T prolongation and torsades de pointes ventricular tachycardia produced by the tetracyclic antidepressant agent maprotiline. American Journal of Cardiology, 1983, 51, 904-906.	0.7	69
105	Three-year clinical follow-up after Palmaz-Schatz stenting. Journal of the American College of Cardiology, 1996, 27, 1185-1191.	1.2	68
106	Enhanced early inhibition of platelet aggregation with an increased bolus of tirofiban. American Journal of Cardiology, 2002, 90, 1421-1423.	0.7	68
107	Study Design of the CLOSURE I Trial. Stroke, 2010, 41, 2872-2883.	1.0	67
108	Transapical and Transaortic Transcatheter Aortic Valve Replacement in the United States. Annals of Thoracic Surgery, 2015, 100, 1718-1727.	0.7	66

#	Article	IF	CITATIONS
109	Impact of Clinical Syndrome Acuity on the Differential Response to 2 Glycoprotein IIb/IIIa Inhibitors in Patients Undergoing Coronary Stenting. Circulation, 2002, 105, 2347-2354.	1.6	64
110	Factors Associated With Vascular Complications in Patients Undergoing Balloon-Expandable Transfemoral Transcatheter Aortic Valve Replacement via Open Versus Percutaneous Approaches. Circulation: Cardiovascular Interventions, 2014, 7, 570-576.	1.4	63
111	Outcomes From Transcatheter Aortic Valve Replacement in Patients With Low-Flow, Low-Gradient Aortic Stenosis and Left Ventricular Ejection Fraction Less Than 30%. JAMA Cardiology, 2019, 4, 64.	3.0	63
112	Triple therapy for acute myocardial infarction: combining fibrinolysis, platelet IIb/IIIa inhibition, and percutaneous coronary intervention. American Journal of Cardiology, 2000, 85, 10-16.	0.7	62
113	Stratification of Outcomes After Transcatheter AorticÂValve Replacement According to Surgical Inoperability for Technical Versus Clinical Reasons. Journal of the American College of Cardiology, 2014, 63, 901-911.	1.2	62
114	The relative performance characteristics of the logistic European System for Cardiac Operative Risk Evaluation score and the Society of Thoracic Surgeons score in the Placement of Aortic Transcatheter Valves trial. Journal of Thoracic and Cardiovascular Surgery, 2014, 148, 2830-2837.e1.	0.4	62
115	Effect of balloon mitral valvuloplasty on exercise capacity, ventilation and skeletal muscle oxygenation. Journal of the American College of Cardiology, 1993, 21, 856-865.	1.2	59
116	1-Year Survival in a Randomized Trial of Facilitated Reperfusion. JACC: Cardiovascular Interventions, 2009, 2, 909-916.	1.1	59
117	Evaluation of Flow After Transcatheter Aortic Valve Replacement in Patients With Low-Flow Aortic Stenosis. JAMA Cardiology, 2016, 1, 584.	3.0	59
118	Cerebral Embolic Exposure During Transfemoral and Transapical Transcatheter Aortic Valve Replacement. Journal of Cardiac Surgery, 2011, 26, 348-354.	0.3	57
119	Safety and Procedural Success of Left Atrial Appendage Exclusion With the Lariat Device. JAMA Internal Medicine, 2015, 175, 1104.	2.6	57
120	Health Status After Transcatheter Versus Surgical Aortic Valve Replacement in Low-Risk Patients With Aortic Stenosis. Journal of the American College of Cardiology, 2019, 74, 2833-2842.	1.2	57
121	Inotropic effect of enoximone in patients with severe heart failure: Demonstration by left ventricular end-systolic pressure-volume analysis. Journal of the American College of Cardiology, 1987, 9, 1117-1123.	1.2	55
122	Sex-Specific Outcomes of TranscatheterÂAortic Valve Replacement With the SAPIEN 3 Valve. JACC: Cardiovascular Interventions, 2018, 11, 13-20.	1.1	55
123	Preventing Coronary Obstruction During Transcatheter Aortic Valve Replacement. JACC: Cardiovascular Interventions, 2021, 14, 941-948.	1.1	55
124	Stroke After Surgical Versus Transfemoral Transcatheter Aortic Valve Replacement in the PARTNER Trial. Journal of the American College of Cardiology, 2018, 72, 2415-2426.	1.2	54
125	Transfemoral Tricuspid Valve Replacement in Patients With TricuspidÂRegurgitation. JACC: Cardiovascular Interventions, 2022, 15, 471-480.	1.1	54
126	Intravascular ultrasonographic assessment of the results of coronary artery stenting. American Heart Journal, 1993, 125, 1576-1583.	1.2	53

#	Article	IF	CITATIONS
127	Rationale, development, implementation, and initial results of a fast track protocol for transfemoral transcatheter aortic valve replacement (TAVR). Catheterization and Cardiovascular Interventions, 2015, 85, 648-654.	0.7	53
128	Interventional Fellowship in Structural and Congenital Heart Disease for Adults. JACC: Cardiovascular Interventions, 2010, 3, e1-e15.	1.1	52
129	Prosthesis-Patient Mismatch After Aortic Valve Replacement in the PARTNER 2 Trial and Registry. JACC: Cardiovascular Interventions, 2021, 14, 1466-1477.	1.1	52
130	Percutaneous Mitral Valve Repair in the Initial EVEREST Cohort. Circulation: Cardiovascular Imaging, 2013, 6, 522-530.	1.3	51
131	Effects of Atrial Fibrillation on Treatment of Mitral Regurgitation in the EVEREST II (Endovascular) Tj ETQq1 2012, 59, 1312-1319.	1 0.784314 rgBT 1.2	/Overlock ] 50
132	The relation of renal function to ischemic and bleeding outcomes with 2 different glycoprotein IIb/IIIa inhibitors: The Do Tirofiban and ReoPro Give Similar Efficacy Outcome (TARGET) trial. American Heart Journal, 2005, 149, 869-875.	1.2	48
133	Transcatheter and Surgical Aortic Valve Replacement in Dialysis Patients: A Propensity-Matched Comparison. Annals of Thoracic Surgery, 2015, 100, 1230-1237.	0.7	48
134	Transcatheter Therapy of Mitral Regurgitation. Circulation, 2014, 130, 1712-1722.	1.6	47
135	Management and immediate outcome of patients with intracoronary thrombus during percutaneous transluminal coronary angioplasty. American Heart Journal, 1992, 124, 1-8.	1.2	46
136	One-year clinical outcomes of protected and unprotected left main coronary artery stenting. European Heart Journal, 2003, 24, 1554-1559.	1.0	46
137	Outcomes in Nonagenarians Undergoing Transcatheter Aortic Valve Replacement in the PARTNER-I Trial. Annals of Thoracic Surgery, 2015, 100, 785-793.	0.7	46
138	Impact of Transcatheter Aortic Valve Replacement on Severity of Chronic Kidney Disease. Journal of the American College of Cardiology, 2020, 76, 1410-1421.	1.2	46
139	Results of Aortic Valve Replacement for Aortic Stenosis With Relatively Low Transvalvular Pressure Gradients. American Journal of Cardiology, 1998, 81, 358-362.	0.7	45
140	Results of the society of cardiac angiography and interventions survey of physicians and training directors on procedures for structural and valvular heart disease. Catheterization and Cardiovascular Interventions, 2010, 76, E106-10.	0.7	44
141	Evaluation of Renal Function Before and After Percutaneous Mitral Valve Repair. Circulation: Cardiovascular Interventions, 2015, 8, .	1.4	44
142	Transcatheter Device Closure of Interatrial Septal Defects in Patients with Hypoxia. Journal of Interventional Cardiology, 2005, 18, 227-232.	0.5	42
143	Prognostic Value of Serial B-Type Natriuretic Peptide Measurement in Transcatheter Aortic Valve Replacement (from the PARTNER Trial). American Journal of Cardiology, 2015, 115, 1265-1272.	0.7	42
144	Anticoagulation After Surgical or Transcatheter Bioprosthetic AorticÂValveÂReplacement. Journal of the American College of Cardiology, 2019, 74, 1190-1200.	1.2	42

HOWARD C HERRMANN, FSCAI

#	Article	IF	CITATIONS
145	Comparison of results of intracoronary stenting in patients with unstable vs. stable angina. Catheterization and Cardiovascular Diagnosis, 1994, 31, 95-101.	0.7	41
146	Characteristics of adult patients with atrial septal defects presenting with paradoxical embolism. Catheterization and Cardiovascular Interventions, 2009, 74, 1066-1069.	0.7	41
147	Consensus Document on Non-Suitability for Transcatheter Mitral Valve Repair by Edge-to-Edge Therapy. Structural Heart, 2021, 5, 227-233.	0.2	41
148	Comparison of degree of platelet inhibition by abciximab versus tirofiban in patients with unstable angina pectoris and non–Q-wave myocardial infarction undergoing percutaneous coronary intervention. American Journal of Cardiology, 2002, 89, 1293-1297.	0.7	40
149	Hemodynamic effects of inhaled nitric oxide in women with mitral stenosis and pulmonary hypertension. American Journal of Cardiology, 2001, 87, 188-192.	0.7	39
150	Initial Experience with a Novel Real-Time Three-Dimensional Intracardiac Ultrasound System to Guide Percutaneous Cardiac Structural Interventions: A Phase 1 Feasibility Study of Volume Intracardiac Echocardiography in the Assessment of Patients with Structural Heart Disease Undergoing Percutaneous Transcatheter Therapy. Journal of the American Society of Echocardiography, 2014, 27, 978-983.	1.2	39
151	Prospective <i>CYP2C19</i> Genotyping to Guide Antiplatelet Therapy Following Percutaneous Coronary Intervention. Circulation Genomic and Precision Medicine, 2020, 13, e002640.	1.6	39
152	Implications of Atrial Fibrillation on the Mechanisms of Mitral Regurgitation and Response to MitraClip in the COAPT Trial. Circulation: Cardiovascular Interventions, 2021, 14, e010300.	1.4	39
153	Cost and contribution margin of transcatheter versus surgical aortic valve replacement. Journal of Thoracic and Cardiovascular Surgery, 2017, 154, 1872-1880.e1.	0.4	38
154	Enoxaparin in Primary and Facilitated Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 2010, 3, 203-212.	1.1	37
155	Association of Tricuspid Regurgitation With Transcatheter Aortic Valve Replacement Outcomes: A Report From The Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy Registry. Annals of Thoracic Surgery, 2018, 105, 1121-1128.	0.7	37
156	Impact of Aortic Root Anatomy and Geometry on Paravalvular Leak in Transcatheter Aortic Valve Replacement With Extremely Large Annuli Using the Edwards SAPIEN 3 Valve. JACC: Cardiovascular Interventions, 2018, 11, 1377-1387.	1.1	37
157	Racial, Ethnic, and Socioeconomic Disparities in Access to Transcatheter Aortic Valve Replacement Within Major Metropolitan Areas. JAMA Cardiology, 2022, 7, 150.	3.0	37
158	Infective Endocarditis Following Transcatheter Aortic Valve Replacement. Circulation: Cardiovascular Interventions, 2019, 12, e007938.	1.4	36
159	Rash with Both Clopidogrel and Ticlopidine in Two Patients Following Percutaneous Coronary Intervention with Drug-Eluting Stents. Annals of Pharmacotherapy, 2006, 40, 1204-1207.	0.9	35
160	Linearity of the left ventricular end-systolic pressure-volume relation in patients with severe heart failure. Journal of the American College of Cardiology, 1989, 14, 127-134.	1.2	33
161	Cardiovascular effects of intracoronary atrial natriuretic peptide administration in man. American Heart Journal, 1990, 120, 308-315. Association between Thrombolysis In Myocardial Infarction myocardial perfusion grade, biomarkers.	1.2	33
162	and clinical outcomes among patients with moderate- to high-risk acute coronary syndromes: Observations from the Randomized Trial to Evaluate the Relative PROTECTion against Post-PCI Microvascular Dysfunction and Post-PCI Ischemia among Antiplatelet and Antithrombotic Agents–Thrombolysis In Myocardial Infarction 30 (PROTECT-TIMI 30). American Heart Journal, 2006, 152, 756-761.	1.2	33

#	Article	IF	CITATIONS
163	Comparison of Effects of Bare Metal Versus Drug-Eluting Stent Implantation on Biomarker Levels Following Percutaneous Coronary Intervention for Non–ST-Elevation Acute Coronary Syndrome. American Journal of Cardiology, 2006, 97, 1473-1477.	0.7	33
164	Platelet glycoprotein IIb/IIIa receptor inhibition as adjunctive treatment during saphenous vein graft stenting: differential effects after randomization to occlusion or filter-based embolic protection. European Heart Journal, 2006, 27, 920-928.	1.0	32
165	Effect of Mitral Valve Gradient After MitraClip on Outcomes in Secondary Mitral Regurgitation. JACC: Cardiovascular Interventions, 2021, 14, 879-889.	1.1	32
166	Late Surgical Mitral Valve Repair after Percutaneous Repair with the MitraClip <sup>®</sup> System. Journal of Cardiac Surgery, 2009, 24, 677-681.	0.3	31
167	Low-Flow Severe Aortic Stenosis. Circulation: Cardiovascular Interventions, 2017, 10, .	1.4	31
168	Percutaneous patent foramen ovale and atrial septal defect closure in adults: Results and device comparison in 100 consecutive implants at a single center. Catheterization and Cardiovascular Interventions, 2005, 64, 197-203.	0.7	30
169	Assessment of Right Ventricular Function by Transthoracic Echocardiography Following Aortic Valve Replacement. Echocardiography, 2014, 31, 552-557.	0.3	30
170	The outcomes of transcatheter aortic valve replacement in a cohort of patients with endâ€stage renal disease. Catheterization and Cardiovascular Interventions, 2016, 87, 1314-1321.	0.7	28
171	Effects of atrial natriuretic peptide on myocardial contractile and diastolic function in patients with heart failure. Journal of the American College of Cardiology, 1992, 20, 98-106.	1.2	27
172	Angiographic variables predict increased riskfor adverse ischemic events after coronarystenting with glycoprotein IIb/IIIa inhibition. Journal of the American College of Cardiology, 2003, 42, 981-988.	1.2	27
173	Outcomes After Transfemoral Transcatheter Aortic Valve Replacement. JACC: Cardiovascular Interventions, 2014, 7, 1245-1251.	1.1	27
174	Effect of Baseline Left Ventricular Ejection Fraction on 2-Year Outcomes After Transcatheter Aortic Valve Replacement. Circulation: Heart Failure, 2019, 12, e005809.	1.6	27
175	Socioeconomic and Geographic Characteristics of Hospitals Establishing Transcatheter Aortic Valve Replacement Programs, 2012–2018. Circulation: Cardiovascular Quality and Outcomes, 2021, 14, e008260.	0.9	27
176	Effect of balloon size and stepwise inflation technique on the acute results of inoue mitral commissurotomy. Catheterization and Cardiovascular Diagnosis, 1993, 28, 199-205.	0.7	25
177	Mortality at 1 year for the direct comparison of tirofiban and abciximab during percutaneous coronary revascularization: do tirofiban and ReoPro give similar efficacy outcomes at trial 1-year follow-up. European Heart Journal, 2005, 26, 2524-2528.	1.0	25
178	Transcatheter aortic valve implantation in patients with ascending aortic dilatation: safety of the procedure and mid-term follow-up. European Journal of Cardio-thoracic Surgery, 2014, 46, 228-233.	0.6	25
179	Effect of SAPIEN 3 Transcatheter Valve Implantation on Health Status in Patients With Severe Aortic Stenosis at Intermediate Surgical Risk. JACC: Cardiovascular Interventions, 2018, 11, 1188-1198.	1.1	25
180	Transcatheter Mitral Valve Therapy in the United States: A Report from the STS/ACC TVT Registry. Annals of Thoracic Surgery, 2022, 113, 337-365.	0.7	25

#	Article	IF	CITATIONS
181	Effectiveness of percutaneous balloon valvuloplasty in adults with pulmonic valve stenosis. American Journal of Cardiology, 1991, 68, 1111-1113.	0.7	24
182	Transfer for Primary Angioplasty. Circulation, 2005, 111, 718-720.	1.6	24
183	Cardiopulmonary bypass and intraâ€eortic balloon pump use is associated with higher short and long term mortality after transcatheter aortic valve replacement: A PARTNER trial substudy. Catheterization and Cardiovascular Interventions, 2015, 86, 316-322.	0.7	24
184	Outcomes, readmissions, and costs in transfemoral and alterative access transcatheter aortic valve replacement in the US Medicare population. Journal of Thoracic and Cardiovascular Surgery, 2017, 154, 1224-1232.e1.	0.4	24
185	Effects of atrial natriuretic factor on coronary hemodynamics and myocardial energetics in patients with heart failure. American Heart Journal, 1988, 115, 1232-1238.	1.2	23
186	Long-term outcome of enoximone therapy in patients with refractory heart failure. American Heart Journal, 1993, 125, 423-429.	1.2	23
187	Comparison of Outcome After Stenting for De Novo Versus Restenotic Narrowings in Native Coronary Arteries. American Journal of Cardiology, 1997, 80, 711-715.	0.7	23
188	Outcomes in 937 Intermediate-Risk Patients Undergoing Surgical Aortic Valve Replacement in PARTNER-2A. Annals of Thoracic Surgery, 2018, 105, 1322-1329.	0.7	23
189	Self-Expanding Valve System for Treatment of Native Aortic Regurgitation by Transcatheter Aortic Valve Implantation (from the STS/ACC TVT Registry). American Journal of Cardiology, 2019, 124, 781-788.	0.7	23
190	Incidence, Predictors, and Outcomes of Acute Kidney Injury in Patients Undergoing Transcatheter Aortic Valve Replacement. Circulation: Cardiovascular Interventions, 2021, 14, e010032.	1.4	23
191	Coronary hemodynamic effects of atrial natriuretic peptide in humans. Journal of the American College of Cardiology, 1990, 16, 1107-1113.	1.2	22
192	The Role of Risk Stratification in the Decision to Provide Upstream Versus Selective Glycoprotein IIb/IIIa Inhibitors for Acute Coronary Syndromes. Journal of the American College of Cardiology, 2006, 47, 529-537.	1.2	22
193	Intracardiac echocardiographyâ€guided transcatheter aortic valve replacement. Catheterization and Cardiovascular Interventions, 2015, 85, 497-501.	0.7	22
194	Hemodynamic Assessment of Patients With Low-Flow, Low-Gradient Valvular Aortic Stenosis. American Journal of Cardiology, 1996, 78, 657-661.	0.7	21
195	The Effect of Diabetes on B-Type Natriuretic Peptide Concentrations in Patients With Acute Dyspnea: An analysis from the Breathing Not Properly Multinational Study. Diabetes Care, 2004, 27, 2398-2404.	4.3	21
196	Outcomes of transcatheter aortic valve replacement in patients with chronic liver disease. Catheterization and Cardiovascular Interventions, 2015, 86, 888-894.	0.7	21
197	Native T1 and T2 mapping by cardiovascular magnetic resonance imaging in pressure overloaded left and right heart diseases. Journal of Thoracic Disease, 2018, 10, 2968-2975.	0.6	21
198	Usefulness of subcutaneous low molecular weight heparin (ardeparin) for reduction of restenosis after percutaneous transluminal coronary angioplasty. American Journal of Cardiology, 1999, 83, 1524-1529.	0.7	20

#	Article	IF	CITATIONS
199	A multicenter study of the tolerability of tirofiban versus placebo in patients undergoing planned intracoronary stent placement. Clinical Therapeutics, 2002, 24, 1332-1344.	1.1	20
200	Comparison of Invasive and Noninvasive Assessment of Aortic Stenosis Severity in the Elderly. Circulation: Cardiovascular Interventions, 2012, 5, 406-414.	1.4	20
201	The society for cardiovascular angiography and interventions structural heart disease early career task force survey results: Endorsed by the society for cardiovascular angiography and interventions. Catheterization and Cardiovascular Interventions, 2012, 80, 706-711.	0.7	20
202	The impact of gender on cardiovascular system calcification in very elderly patients with severe aortic stenosis. International Journal of Cardiovascular Imaging, 2016, 32, 173-179.	0.7	20
203	Surgical Treatment of Patients With Infective Endocarditis After Transcatheter Aortic Valve Implantation. Journal of the American College of Cardiology, 2022, 79, 772-785.	1.2	20
204	Comparison of results of percutaneous balloon valvuloplasty in patients with mild and moderate mitral stenosis to those with severe mitral stenosis. American Journal of Cardiology, 1993, 71, 1300-1303.	0.7	19
205	The Effect of Surgical and Transcatheter Aortic Valve Replacement on Mitral Annular Anatomy. Annals of Thoracic Surgery, 2013, 95, 614-619.	0.7	19
206	Pathology of balloonâ€expandable transcatheter aortic valves. Catheterization and Cardiovascular Interventions, 2017, 90, 1048-1057.	0.7	19
207	Complete 2-Year Results Confirm Bayesian Analysis of the SURTAVI Trial. JACC: Cardiovascular Interventions, 2020, 13, 323-331.	1.1	19
208	Temporal Trends, Characteristics, and Outcomes of Infective Endocarditis After Transcatheter Aortic Valve Replacement. Clinical Infectious Diseases, 2021, 73, e3750-e3758.	2.9	19
209	Patient satisfaction is comparable to early discharge versus overnight observation after elective percutaneous coronary intervention. Journal of Invasive Cardiology, 2009, 21, 464-7.	0.4	19
210	Outcome of Flow-Gradient Patterns of Aortic Stenosis After Aortic Valve Replacement. Circulation: Cardiovascular Interventions, 2020, 13, e008792.	1.4	18
211	Rationale and design of the SMall Annuli Randomized To Evolut or SAPIEN Trial (SMART Trial). American Heart Journal, 2022, 243, 92-102.	1.2	18
212	Radiation-induced cardiovascular dysfunction. American Journal of Cardiology, 1996, 78, 114-115.	0.7	17
213	The relationship of obesity to ischemic outcomes following coronary stent placement in contemporary practice. Catheterization and Cardiovascular Interventions, 2006, 67, 563-570.	0.7	17
214	"Double wire―angioâ€seal closure technique after balloon aortic valvuloplasty. Catheterization and Cardiovascular Interventions, 2010, 75, 488-492.	0.7	17
215	The Progression of a Transcatheter Aortic Valve Program: A Decision Analysis of More Than 680 Patient Referrals. Annals of Thoracic Surgery, 2011, 92, 2072-2077.	0.7	17
216	Percutaneous Closure of a Left Ventricular Pseudoaneurysm After Sapien XT Transapical Transcatheter Aortic Valve Replacement. JACC: Cardiovascular Interventions, 2012, 5, e37-e38.	1.1	17

#	Article	IF	CITATIONS
217	Procedural and clinical outcomes of the valveâ€inâ€valve technique for severe aortic insufficiency after balloonâ€expandable transcatheter aortic valve replacement. Catheterization and Cardiovascular Interventions, 2012, 80, 139-147.	0.7	17
218	Transcatheter mitral valve replacement: latest advances and future directions. Annals of Cardiothoracic Surgery, 2021, 10, 85-95.	0.6	17
219	Mitral Regurgitation in Low-Flow, Low-Gradient Aortic Stenosis PatientsÂUndergoing TAVR. JACC: Cardiovascular Interventions, 2020, 13, 567-579.	1.1	16
220	Use of a new 8 French intracardiac echocardiographic catheter to guide device closure of atrial septal defects and patent foramen ovale in small children and adults: initial clinical experience. Journal of Invasive Cardiology, 2005, 17, 540-5.	0.4	16
221	Left ventricular assist without thoracotomy: Clinical experience with the dennis method. Annals of Thoracic Surgery, 1994, 57, 880-885.	0.7	15
222	The Effect of Post-Dilatation on Outcomes in the PARTNER 2 SAPIEN 3ÂRegistry. JACC: Cardiovascular Interventions, 2018, 11, 1710-1718.	1.1	15
223	5-Year Outcomes Comparing Surgical Versus Transcatheter Aortic Valve Replacement in Patients With ChronicÂKidney Disease. JACC: Cardiovascular Interventions, 2021, 14, 1995-2005.	1.1	15
224	Predictors of clinical outcome following percutaneous intervention for in-stent restenosis. American Journal of Cardiology, 2000, 85, 1427-1431.	0.7	14
225	Analysis of Early Out-of Hospital Mortality After Transcatheter Aortic Valve Implantation Among Patients With Aortic Stenosis Successfully Discharged from the Hospital and Alive at 30 Days (from) Tj ETQq1 1550-1555.	1 0.784314 0.7	⊦rg₽Ţ /Overlo
226	Combination therapy with clopidogrel and aspirin after coronary stenting. Catheterization and Cardiovascular Interventions, 2000, 50, 276-279.	0.7	13
227	Hemodynamic effects and longâ€ŧerm outcome of percutaneous balloon valvuloplasty in patients with mitral stenosis and atrial fibrillation. Clinical Cardiology, 2000, 23, 673-677.	0.7	13
228	Percutaneous transcatheter closure of patent foramen ovale with the Amplatzer Cribriform septal occluder. Catheterization and Cardiovascular Interventions, 2008, 71, 383-387.	0.7	13
229	Transcatheter Aortic Valve Replacement With Coronary Artery Protection Performed in a Patient With an Anomalous Left Main Coronary Artery. Journal of the American College of Cardiology, 2012, 60, e9.	1.2	13
230	Identifying Patients Who Do Not Benefit From Transcatheter Aortic Valve Replacement. Circulation: Cardiovascular Interventions, 2014, 7, 136-138.	1.4	13
231	5-Year Follow-Up From the PARTNER 2 Aortic Valve-in-Valve Registry for Degenerated Aortic SurgicalÂBioprostheses. JACC: Cardiovascular Interventions, 2022, 15, 698-708.	1.1	13
232	Long-Term Outcomes After Infective Endocarditis After Transcatheter Aortic Valve Replacement. Circulation, 2020, 142, 1497-1499.	1.6	13
233	Techniques for assessing inotropic effects of drugs in patients with heart failure: Application to the evaluation of nicardipine. American Heart Journal, 1990, 119, 451-456.	1.2	12
234	Tirofiban: an investigational plateletglycoprotein IIb/IIIa receptor antagonist. Expert Opinion on Investigational Drugs, 1997, 6, 1257-1267.	1.9	12

#	Article	IF	CITATIONS
235	Update and rationale for ongoing acute myocardial infarction trials: Combination therapy, facilitation, and myocardial preservation. American Heart Journal, 2006, 151, S30-S39.	1.2	12
236	Combined Transaortic Transcatheter Valve Replacement and Thoracic Endografting. Annals of Thoracic Surgery, 2014, 97, 696-698.	0.7	12
237	SCAI publications committee manual of standard operating procedures. Catheterization and Cardiovascular Interventions, 2020, 96, 145-155.	0.7	12
238	Stroke Complicating Infective Endocarditis After Transcatheter Aortic Valve Replacement. Journal of the American College of Cardiology, 2021, 77, 2276-2287.	1.2	12
239	Thrombus predicts ischemic complications during percutaneous coronary intervention in saphenous vein grafts: Results from TARGET (do tirofiban and reopro give similar efficacy trial?). Catheterization and Cardiovascular Interventions, 2007, 69, 623-629.	0.7	11
240	The Clinical Implications of Body Surface Area as a Poor Proxy for Cardiac Output. Structural Heart, 2021, 5, 582-587.	0.2	11
241	Adult cardiovascular physician resources and needs assessment. Journal of the American College of Cardiology, 1995, 26, 1125-1132.	1.2	10
242	Percutaneous Ventricular Septal Defect Closure After Sapien 3 Transcatheter Aortic Valve Replacement. JACC: Cardiovascular Interventions, 2015, 8, e109-e110.	1.1	10
243	Neutrophilâ€ŧo‣ymphocyte Ratios in Patients Undergoing Aortic Valve Replacement: The PARTNER Trials and Registries. Journal of the American Heart Association, 2022, 11, .	1.6	10
244	Alcohol septal ablation complicated by complete heart block and permanent pacemaker failure. Catheterization and Cardiovascular Interventions, 2003, 58, 189-193.	0.7	9
245	Percutaneous Treatment of Valvular Heart Disease: Catheterâ€Based Aortic Valve Replacement and Mitral Valve Repair Therapies. The American Journal of Geriatric Cardiology, 2006, 15, 291-301.	0.7	9
246	Percutaneous Closure of an Aortic Pseudoaneurysm Due to Saphenous Vein Graft Dehiscence With an Amplatzer Vascular Plug. JACC: Cardiovascular Interventions, 2013, 6, 1103-1104.	1.1	9
247	Estimation of oxygen consumption in elderly patients with aortic stenosis. Catheterization and Cardiovascular Interventions, 2014, 83, E128-33.	0.7	9
248	Pulmonary Hypertension is a Manifestation of Congestive Heart Failure and Left Ventricular Diastolic Dysfunction in Octogenarians with Severe Aortic Stenosis. Pulmonary Circulation, 2015, 5, 521-526.	0.8	9
249	Echocardiographic determinants of LV functional improvement after transcatheter aortic valve replacement. Catheterization and Cardiovascular Interventions, 2016, 87, 1164-1172.	0.7	9
250	Association Between 90-Minute Door-to-Balloon Time, Selective Exclusion of Myocardial Infarction Cases, and Access Site Choice. Circulation: Cardiovascular Interventions, 2020, 13, e009179.	1.4	9
251	Infective Endocarditis Caused by Staphylococcus aureus After Transcatheter Aortic Valve Replacement. Canadian Journal of Cardiology, 2022, 38, 102-112.	0.8	9
252	Single large-balloon percutaneous mitral valvuloplasty. Catheterization and Cardiovascular Diagnosis, 1989, 17, 59-61.	0.7	8

#	Article	IF	CITATIONS
253	A dosimetric comparison of conventional vs conformal external beam irradiation of a stented coronary artery utilizing a new fluoroscopic imaging detector system. Cardiovascular Radiation Medicine, 1999, 1, 80-85.	0.7	8
254	Facilitated percutaneous coronary intervention: A novel concept in expediting and improving acute myocardial infarction care. American Heart Journal, 2000, 140, S125-S135.	1.2	8
255	The role of platelets and platelet inhibition in acute myocardial infarction. Coronary Artery Disease, 2003, 14, 357-363.	0.3	8
256	Aortic and Mitral Valve Replacement Versus Transcatheter Aortic Valve Replacement in Propensity-Matched Patients. Annals of Thoracic Surgery, 2014, 98, 1267-1273.	0.7	7
257	Patient selection reduces thrombotic complications of emergent stenting for failed ptca. Catheterization and Cardiovascular Diagnosis, 1995, 34, 286-292.	0.7	6
258	Prevention of Cardiovascular Events after Percutaneous Coronary Intervention. New England Journal of Medicine, 2004, 350, 2708-2710.	13.9	6
259	Novel use of perfusion balloon inflation to avoid outflow tract obstruction during transcatheter mitral valveâ€inâ€valve replacement. Catheterization and Cardiovascular Interventions, 2018, 92, 601-606.	0.7	6
260	Oral anticoagulant use in patients with atrial fibrillation and mitral valve repair. American Heart Journal, 2021, 232, 1-9.	1.2	6
261	Utilization, Costs, and Outcomes of Conscious Sedation Versus General Anesthesia for Transcatheter Aortic Valve Replacement. Circulation: Cardiovascular Interventions, 2021, 14, e010310.	1.4	6
262	Editorial comment: Top 10 reasons to use the Inoue balloon. Catheterization and Cardiovascular Diagnosis, 1996, 38, 15-15.	0.7	5
263	Mechanical Prosthetic Valve Thrombosis: Case Report and Review of the Literature. , 1998, 6, 253-259.		5
264	New Transcatheter Aortic Valve Prosthesis Sets a New Standardâ^—. Journal of the American College of Cardiology, 2014, 64, 2244-2245.	1.2	5
265	Prosthesis–Patient Mismatch After Transcatheter Aortic Valve Replacement. JACC: Cardiovascular Interventions, 2019, 12, 2183-2185.	1.1	5
266	Pressure loss recovery in aortic valve stenosis: Contemporary relevance. Catheterization and Cardiovascular Interventions, 2021, , .	0.7	5
267	Snare-Assisted Valve Positioning of Self-Expanding Valves for Transcatheter Aortic Valve Replacement. JACC: Case Reports, 2021, 3, 658-662.	0.3	5
268	One-year follow-up results of "culprit―versus multivessel coronary angioplasty trial. American Journal of Cardiology, 1993, 71, 1431-1433.	0.7	4
269	Influence of vessel diameter on the efficacy of distal protection devices during saphenous vein graft intervention. American Journal of Cardiology, 2005, 95, 651-654.	0.7	4
270	All Aortic Stenoses Are Not Created Equalâ^—. Journal of the American College of Cardiology, 2015, 65, 654-656.	1.2	4

HOWARD C HERRMANN, FSCAI

#	Article	IF	CITATIONS
271	Transcatheter Mitral Valve ReplacementÂClears the First Hurdle â^—. Journal of the American College of Cardiology, 2017, 69, 392-394.	1.2	4
272	Transcatheter aortic valve replacement for bicuspid aortic stenosis 13 years post heart transplant. Cardiovascular Revascularization Medicine, 2017, 18, 32-33.	0.3	4
273	Impact of Echocardiographic Parameters on Recurrent Stroke in the Randomized REDUCE PFO Cryptogenic Stroke Trial. Structural Heart, 2021, 5, 367-375.	0.2	4
274	Measuring TAVR Prosthesis Gradient Immediately Post-Procedure May Underestimate its Significance. JACC: Cardiovascular Interventions, 2022, 15, 120-121.	1.1	4
275	To close or not to close: PFO, sex and cerebrovascular events. Journal of Invasive Cardiology, 2006, 18, E292-3.	0.4	4
276	Failure of endocardial biopsy from the internal jugular vein due to endocardial scar: A new indication for the femoral venous approach. Catheterization and Cardiovascular Diagnosis, 1992, 27, 289-290.	0.7	3
277	IIb or not IIb: When, how, and which GP IIb/IIIa inhibitor?. Catheterization and Cardiovascular Interventions, 2001, 52, 433-434.	0.7	3
278	B-Type Natriuretic Peptide Levels in Patients in the Emergency Department With Possible Heart Failure and Previous Stable Angina Pectoris and/or Healed Myocardial Infarction. American Journal of Cardiology, 2005, 96, 1370-1373.	0.7	3
279	Transcatheter Aortic Valve Implantation. Circulation: Cardiovascular Interventions, 2008, 1, 159-160.	1.4	3
280	Quantification of the effect of clopidogrel on enzymatic infarct size related to a percutaneous coronary intervention in patients with acute coronary syndromes. Coronary Artery Disease, 2013, 24, 321-327.	0.3	3
281	Response to Letters Regarding Article, "Infective Endocarditis After Transcatheter Aortic Valve Implantation: Results From a Large Multicenter Registryâ€: Circulation, 2015, 132, e372-4.	1.6	3
282	Implications of Left Ventricular Geometry in Low-Flow Aortic Stenosis. JACC: Cardiovascular Imaging, 2019, 12, 367-368.	2.3	3
283	Early outcomes from the <scp>CLASP IID</scp> trial rollâ€in cohort for prohibitive risk patients with degenerative mitral regurgitation. Catheterization and Cardiovascular Interventions, 2021, 98, E637-E646.	0.7	3
284	Small Annulus, Hemodynamic Status, and TAVR. JACC: Cardiovascular Interventions, 2021, 14, 1229-1230.	1.1	3
285	Transcatheter Mitral Valve Replacement: Rationale and Current Status. Annual Review of Medicine, 2020, 71, 249-261.	5.0	3
286	Unprotected left main "kissing" stent implantation with a percutaneous ventricular assist device. Journal of Invasive Cardiology, 2004, 16, 683-4.	0.4	3
287	Left main coronary embolism. Journal of Invasive Cardiology, 2006, 18, 296.	0.4	3
288	Mitral Valve Infective Endocarditis after Trans-Catheter Aortic Valve Implantation. American Journal of Cardiology, 2022, 172, 90-97.	0.7	3

#	Article	IF	CITATIONS
289	Sex Differences in Infective Endocarditis After Transcatheter Aortic Valve Replacement. Canadian Journal of Cardiology, 2022, 38, 1418-1425.	0.8	3
290	Response to Letter Regarding Article, "Long-Term Outcomes of Inoperable Patients With Aortic Stenosis Randomly Assigned to Transcatheter Aortic Valve Replacement or Standard Therapy― Circulation, 2015, 132, e118-9.	1.6	2
291	Transcatheter Aortic Valve Replacement for Failed Surgical Bioprostheses: Insights from the PARTNER II Valve-in-Valve Registry on Utilizing Baseline Computed-Tomographic Assessment. Structural Heart, 2017, 1, 34-39.	0.2	2
292	Transcatheter Aortic Valve Replacement After Prior Mitral Valve Surgery: Results From the Transcatheter Valve Therapy Registry. Annals of Thoracic Surgery, 2020, 109, 1789-1796.	0.7	2
293	Hemodynamic Effects of Valve Asymmetry in Sapien 3 Transcatheter Aortic Valves. Journal of Invasive Cardiology, 2018, 30, 138-143.	0.4	2
294	The Clinical Course of Patients with Atrial Fibrillation and Flutter Admitted to Medical Intensive Care Units. Journal of Intensive Care Medicine, 1989, 4, 112-116.	1.3	1
295	Improving the results of bail-out stenting. Catheterization and Cardiovascular Diagnosis, 1995, 35, 210-210.	0.7	1
296	Acute Decompensation of Hypertrophic Obstructive Cardiomyopathy Secondary to A-V Disassociation: Successful Treatment with a Combination of Alcohol Septal Ablation and Permanent Pacemaker. Journal of Interventional Cardiology, 2005, 18, 401-406.	0.5	1
297	Percutaneous valve therapies. Current Treatment Options in Cardiovascular Medicine, 2005, 7, 477-482.	0.4	1
298	Overestimation of Paravalvular Leak WithÂEdwards SAPIEN 3 Transcatheter Aortic ValveÂReplacement. JACC: Cardiovascular Interventions, 2015, 8, e69-e71.	1.1	1
299	MitraClip for Secondary Mitral Regurgitation. JACC: Case Reports, 2021, 3, 361-365.	0.3	1
300	Patient and Staff Perceptions of Universal Severe Acute Respiratory Syndrome Coronavirus 2 Screening Prior to Cardiac Catheterization and Electrophysiology Laboratory Procedures. Circulation: Cardiovascular Interventions, 2020, 13, e009975.	1.4	1
301	Complications and long-term results of percutaneous balloon valvuloplasty for mitral stenosis. Catheterization and Cardiovascular Diagnosis, 1998, 43, 140-140.	0.7	0
302	Anticoagulation Before and After Percutaneous Balloon Valvuloplasty for Mitral Stenosis. Journal of Interventional Cardiology, 2000, 13, 389-394.	0.5	0
303	ACC/AHA guidelines for coronary artery bypass graft surgery: executive summary and recommendations. Indian Journal of Thoracic and Cardiovascular Surgery, 2000, 16, 110-128.	0.2	0
304	Does primary stent implantation increase late mortality after myocardial infarction?. Catheterization and Cardiovascular Interventions, 2001, 54, 333-334.	0.7	0
305	The impact of age, race and gender on the ability of B-type natriuretic peptide to aid in the emergency diagnosis of heart failure: results from the breathing not properly (BNP) multinational study. Journal of Cardiac Failure, 2003, 9, S36.	0.7	0
306	Greater Benefit of Early Invasive Strategy for Unstable Angina and Non-ST Elevation Myocardial Infarction in United States Compared With Non-United States Patients. Critical Pathways in Cardiology, 2004, 3, 95-100.	0.2	0

#	Article	IF	CITATIONS
307	Filterwireâ,"¢ distal embolic protection device for vein graft stenting: Initial single-center experience. Clinical Cardiology, 2005, 28, 556-560.	0.7	0
308	Transcatheter Valve Repair. Circulation, 2006, 114, .	1.6	0
309	TCT-773 The Prognostic Significance of Changes in B-type Naturetic Peptide (BNP) after Transcatheter Aortic Valve Replacement (TAVR): THE PARTNER I EXPERIENCE. Journal of the American College of Cardiology, 2013, 62, B235.	1.2	0
310	Continuing Medical Education Activity inEchocardiography. Echocardiography, 2014, 31, 551-551.	0.3	0
311	THE IMPACT OF GENDER ON THE CALCIFICATION IN THE CARDIOVASCULAR SYSTEM IN ELDERLY PATIENTS. Journal of the American College of Cardiology, 2014, 63, A1054.	1.2	0
312	IMPACT OF BASELINE LEFT VENTRICULAR FUNCTION AND AORTIC VALVE GRADIENT ON OUTCOMES IN PATIENTS TREATED WITH TRANSCATHETER AORTIC VALVE REPLACEMENT: RESULTS FROM THE TVT REGISTRY. Journal of the American College of Cardiology, 2015, 65, A1968.	1.2	0
313	TAVR IS SAFE AND IMPROVES CARDIAC FUNCTION IN PATIENTS WITH EXTREMELY LOW EJECTION FRACTIONS. Journal of the American College of Cardiology, 2017, 69, 1035.	1.2	0
314	Impact of Resting Heart Rate at 30 Days Following Transcatheter or Surgical Aortic Valve Replacement and Cardiovascular Outcomes: Insights from The PARTNER 2 Trial. Structural Heart, 2018, 2, 441-447.	0.2	0
315	Who should get surgical aortic valve replacement in the era of transcatheter aortic valve replacement?—interventional cardiology perspective. Annals of Cardiothoracic Surgery, 2020, 9, 490-492.	0.6	0
316	Lack of Association Between Percutaneous Coronary Intervention and Transcatheter Aortic Valve Replacement Outcomes in New York Hospitals. Circulation: Cardiovascular Interventions, 2021, 14, e010750.	1.4	0
317	Vasospasm-Induced Heart Block. Journal of Cardiovascular Nursing, 2001, 15, 105-108.	0.6	0
318	Safety of vascular closure devicesare women different?. Journal of Invasive Cardiology, 2004, 16, 464-5.	0.4	0
319	PCI in African-American women: closing the gender gap. Journal of Invasive Cardiology, 2007, 19, 129-30.	0.4	0
320	Percutaneous valve repair and placement. Journal of Invasive Cardiology, 2004, 16, 59S-64S.	0.4	0
321	The futurepanel discussion. Journal of Invasive Cardiology, 2004, 16, 65S-66S.	0.4	0
322	Left Ventricular Hypertrophy and Hypertrophic Cardiomyopathy in Adult Solid Organ Transplant Recipients. Transplantation Direct, 2022, 8, e1279.	0.8	0